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The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two of the most impor-
tant known risk factors for developing Alzheimer disease (AD). The diagnosis of AD based
on clinical symptoms alone is known to have poor specificity; recently developed diagnostic
criteria based on biomarkers that reflect underlying AD neuropathology allow better
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assessment of the strength of the associations of risk factors with AD. Accordingly, we
examined the global and age-specific association between APOE genotype and AD by
using the A/T/N classification, relying on the cerebrospinal fluid (CSF) levels of β-amyloid
peptide (A, β-amyloid deposition), phosphorylated tau (T, pathologic tau), and total tau (N,
neurodegeneration) to identify patients with AD.
Methods and findings
This case–control study included 1,593 white AD cases (55.4% women; mean age 72.8
[range = 44–96] years) with abnormal values of CSF biomarkers from nine European mem-
ory clinics and the American Alzheimer’s Disease Neuroimaging Initiative (ADNI) study. A
total of 11,723 dementia-free controls (47.1% women; mean age 65.6 [range = 44–94]
years) were drawn from two longitudinal cohort studies (Whitehall II and Three-City), in
which incident cases of dementia over the follow-up were excluded from the control popula-
tion. Odds ratio (OR) and population attributable fraction (PAF) for AD associated with
APOE genotypes were determined, overall and by 5-year age categories. In total, 63.4% of
patients with AD and 22.6% of population controls carried at least one APOE ε4 allele. Com-
pared with non-ε4 carriers, heterozygous ε4 carriers had a 4.6 (95% confidence interval
4.1–5.2; p < 0.001) and ε4/ε4 homozygotes a 25.4 (20.4–31.2; p < 0.001) higher OR of AD
in unadjusted analysis. This association was modified by age (p for interaction < 0.001). The
PAF associated with carrying at least one ε4 allele was greatest in the 65–70 age group
(69.7%) and weaker before 55 years (14.2%) and after 85 years (22.6%). The protective
effect of APOE ε2 allele for AD was unaffected by age. Main study limitations are that analy-
ses were based on white individuals and AD cases were drawn from memory centers, which
may not be representative of the general population of patients with AD.
Conclusions
In this study, we found that AD diagnosis based on biomarkers was associated with APOE
ε4 carrier status, with a higher OR than previously reported from studies based on only clini-
cal AD criteria. This association differs according to age, with the strongest effect at 65–70
years. These findings highlight the need for early interventions for dementia prevention to
mitigate the effect of APOE ε4 at the population level.
Author summary
Why was this study done?
• The ε4 allele of apolipoprotein E (APOE) gene (APOE4) and increasing age are two of
the most important known risk factors for developing Alzheimer disease (AD).
• The recent development of diagnostic criteria based on biomarkers that reflect brain β-
amyloid and tau lesions (β-amyloid deposition, pathologic tau, neurodegeneration [A/
T/N] classification]) increases homogeneity in diagnosed cases.
• The strength of association of AD with risk factors can be better determined using bio-
marker-based AD compared with AD diagnosis based only on clinical criteria because
PLOS MEDICINE APOE and risk of Alzheimer disease
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003289 August 20, 2020 2 / 20
CSF_biomarkers_data_pdf/12030084. The
Whitehall-II Study is managed by the Department
of Epidemiology and Public Health of the University
College of London (UCL). The list of the principal




coming from the Whitehall-II Study can be made




information: whitehall2@ucl.ac.uk. The Alzheimer’s
Disease Neuroimaging Initiative (ADNI) is a
longitudinal multicenter study designed to develop
clinical, imaging, genetic, and biochemical
biomarkers for the early detection and tracking of
Alzheimers disease. The principal investigator is Pr
Michael W. Weiner, Professor of Radiology,
Medicine, Psychiatry, and Neurology at the
University of California San Francisco. Data coming
from the ADNI study can be made freely available
to interested researchers upon request: http://adni.
loni.usc.edu/data-samples/access-data/. Contact
information: adni-study@usc.edu. The 3-City Study
is managed by the INSERM Unit U708, Université
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the latter are known to lack specificity as a result of difficulties in ruling out other causes
of dementia.
What did the researchers do and find?
• We compared the overall and age-specific association between APOE4 and AD using a
case–control study that included 1,593 AD cases from memory clinics with positive
cerebrospinal fluid biomarkers and 11,723 dementia-free controls drawn from two lon-
gitudinal cohort studies.
• The use of a large number of cases and controls allows assessment of whether the associ-
ation between APOE4 and AD is dependent on age.
• Compared with controls, patients with AD were more likely to carry one APOE4 (odds
ratio [OR] = 4.6) or two APOE4 (OR = 25.3). This association was significantly modified
by age, with the strongest association seen between 65 and 70 years of age and weaker
associations at the two tails of the age distribution.
What do these findings mean?
• Incorporating biomarkers for diagnosis of AD identified an association with APOE4
that is apparently greater than has been previously reported using clinical diagnosis of
the disease.
• The impact of APOE4 on the risk of AD was strongest between the 65 and 70 years of
age, earlier than the mean age at diagnosis in this study, which was 72.8 years.
Introduction
Apolipoprotein E (APOE) ε4 allele is the strongest known genetic risk factor for Alzheimer
disease (AD) in the general population [1]. The three most common alleles of the APOE gene
are ε2, ε3, and ε4; they encode for three isoform proteins differing in two single cysteine-to-
arginine amino acid substitution at positions 112 and 158 [2]. The ε3 allele is the most com-
mon allele in the population and is used as the reference to estimate risk of AD. Current evi-
dence suggests that ε4 heterozygote carriers have an overall 3-fold increased risk of AD,
whereas ε4 homozygote carriers have up to a 15-fold increased risk [3]. Conversely, the ε2
allele is associated with nearly 50% lower risk of AD [4]. The mechanisms underlying the rela-
tionship between APOE ε4 and AD are thought to be complex [5], involving β-amyloid (Aβ)
peptide clearance [6] as well as a direct role on neuronal death [7,8] and on phosphorylation of
tau [9].
Beyond individual genetic susceptibilities, increasing age is the main risk factor of AD [10].
Rare before the age of 60, AD affects up to 20% of the population after 80 years [11]. Accord-
ingly, the objective of the present study was to examine whether age modifies the association
between APOE genotype and risk of AD. Indeed, much of the evidence in this domain is from
studies undertaken before the 2000s, when the diagnosis of AD was based solely on clinical
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criteria. Diagnosis of AD based on clinical criteria is marked by poor overall specificity, rang-
ing from 40% to 70% compared with neuropathologic examination [12], which can lead to
misclassification bias in studies [13]. Furthermore, the rate of false-positive diagnosis of AD
may be influenced by the APOE status and age of patients, as the proportion of some differen-
tial diagnoses, like frontotemporal dementia, is higher in younger patients, leading to differen-
tial misclassification bias and unpredictable effect when estimating the strength of associations
in case–controls studies [14].
Tau and Aβ peptide biomarkers are now incorporated in the new research diagnostic crite-
ria in order to increase the biological homogeneity in diagnosed AD cases [15,16], and the β-
amyloid deposition, pathologic tau, neurodegeneration (A/T/N) classification has recently
been proposed as an unbiased biological definition of the disease [17]. Therefore, the present
study aims to examine the global and age-specific association of APOE status with AD risk
using a case–control design based on data on AD cases from nine European memory centers
and the American Alzheimer’s Disease Neuroimaging Initiative (ADNI) study [18], in which
diagnosis were based both on clinical criteria [16] and on positive-biomarkers profile accord-
ing to A/T/N classification [17]. Contrary to previous case–controls studies in which controls
may have also included persons at a prodromal stage of AD, we chose a first control group
drawn from two large European longitudinal cohorts: the Whitehall II study [19] and Three-
City Study [20], in which prevalent and incident cases of dementia over the follow-up were
excluded. Furthermore, the complementarity in terms of age of these two studies ensures a
wide age range to match that of patients with AD. We also considered a second independent
control group, recruited from individuals seen at the same memory clinics as the AD cases,
who were characterized by a normal profile of cerebrospinal fluid (CSF) AD biomarkers.
Methods
This study is reported following the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines (S1 STROBE Checklist). The study objectives and analysis
plan were developed prior to data manipulation as an MSc internship project (S1 Text). The
analyses undertaken in response to reviewers’ suggestions are presented in post hoc analyses.
Patients with AD
Data were drawn from nine memory centers in Europe (France [Paris, Rouen, Montpellier],
Sweden [Gothenburg], Spain [Barcelona], Italia [Perugia], Belgium [Antwerp], and Germany
[Göttingen and Munich]) and the ADNI study (see www.adni-info.org) [18]. Patients with AD
included in the analyses were white and had a clinical diagnosis of probable AD [16], data on
APOE genotype, and a positive-biomarkers profiles according to the A/T/N classification, and
they are referred to as “CSF AD cases” in this study. Positivity of biomarkers profile was
defined as abnormal values for CSF Aβ42 (A+) and CSF tau phosphorylated at threonine 181
(p-tau 181, T+), according to the reference values used in the memory centers. Assessment of
CSF p-tau 181 was missing in one center (Gothenburg); biomarker positivity therefore relied
only on CSF Aβ42 and CSF tau for this center. CSF Aβ40 was not measured, which precluded
use of the amyloid ratio in the analyses. The number of patients included from each center as
well as center-specific cutoffs of the CSF biomarkers are presented in S1 Table.
Controls
“Population controls” came from two large European cohort studies of community-dwelling
people with a focus on cognitive aging: the Whitehall II study (United Kingdom) and the
Three-City Study (France). Design and procedures of these studies have been reported
PLOS MEDICINE APOE and risk of Alzheimer disease
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previously [19,20]. Data on controls from these studies were drawn from the wave when
APOE genotype was determined (baseline for Three-City Study, third clinical screening for
Whitehall II). Both studies were complementary in terms of age of participants, as Whitehall II
study included mainly middle-aged participants, and Three-City Study included persons 65
years or more at baseline. Therefore, controls less than 65 years old came from Whitehall II
and those aged 65 years or more came from the Three-City Study. CSF biomarkers were not
available in either of these studies. We excluded prevalent cases of dementia at measurement
of APOE genotype and incident cases over the subsequent follow-up: 20 years in the Whitehall
II study (168 incident cases) and 8 years in the Three-City Study (182 prevalent cases and 220
incident cases). In Whitehall II, dementia cases were ascertained based on linkage for all par-
ticipants to electronic health records. Three registers (the national hospital episode statistics
database, the Mental Health Services Data Set, and the mortality register) were used for
dementia ascertainment by using ICD-10 codes F00-F03, F05.1, G30, and G31. In the Three-
City Study, the detection of dementia cases was based on a three-step procedure at baseline
and at each follow-up (neuropsychological evaluation, neurological examination, validation by
an independent committee) as previously described [20]. Nonwhite participants were excluded
in both studies.
We also used a second set of controls, identified as “CSF controls,” consisting of white indi-
viduals recruited at the memory centers with normal values for all CSF biomarkers (Aβ42, tau,
p-tau 181). This population consisted mainly of patients assessed for cognitive disorders other
than AD and/or persons referred to the memory clinic who turned out not to have AD.
Ethics statement
Ethical clearance was obtained by the institutional review boards of all participating sites
(European memory centers and ADNI study sites). Ethical approval for the Whitehall II study
was obtained from the NHS London—Harrow Research Ethics Committee (reference number
85/0938). The study protocol of Three-City Study was approved by the Ethical Committee of
Kremlin-Bicetre University Hospital. All participants provided written, informed consent.
CSF biomarkers assessment
For the European memory centres, CSF levels of Aβ42, total tau, and p-tau 181 were assessed
with the commercially available sandwich ELISA INNOTEST, using the manufacturer’s proce-
dures (Fujirebio Europe NV, formerly Innogenetics NV).
In the ADNI study, CSF collection and processing are described in detail at http://adni.loni.
usc.edu/methods/. Briefly, CSF Aβ42, tau, and p-tau 181 levels were quantified using multiplex
xMAP Luminex platform (Luminex Corporation, Austin, TX) with Innogenetics (INNO-BIA
AlzBio3; Ghent, Belgium) immunoassay kit–based research-use-only reagents containing
4D7A3 monoclonal antibody for Aβ42, AT120 monoclonal antibody for tau, and AT270
monoclonal antibody for p-tau 181.
The center-specific CSF biomarker cutoffs used in clinical setting were provided by each
participating center and are presented in S1 Table.
APOE genotyping
In the European memory centers, APOE genotype was determined using standard polymerase
chain reaction and restriction enzyme digestion according to established standard protocols
[21].
In the ADNI study, APOE genotypes were determined by using DNA extracted by Cogenics
from a 3-mL aliquot of EDTA blood. Polymerase chain reaction amplification was followed by
PLOS MEDICINE APOE and risk of Alzheimer disease
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HhaI restriction enzyme digestion, resolution on 4% Metaphor Gel, and visualization by ethid-
ium bromide staining [22].
In Whitehall II and the Three-City Study, two TaqMan assays (Rs429358 and Rs7412,
Assay-On-Demand, Applied Biosystems) were used and run on a 7900HT analyzer (Applied
Biosystems), and APOE genotypes were indicated by the Sequence Detection Software version
2.0 (Applied Biosystems) [23,24].
Covariates
Age in the analysis was set as age at CSF collection for AD cases and CSF controls and at blood
collection for APOE genotyping in the population controls. As CSF biomarker assessment was
performed as part of the AD diagnostic procedure, age at CSF collection was considered as a
surrogate of age at diagnosis. Mini-Mental Status Examination (MMSE) score was taken from
the date closest to the lumbar puncture for patients with AD and APOE determination in the
population controls. Level of education was considered in three categories: no education to
primary school, secondary school to high school, and baccalaureate or university degree.
In a subsample, data on the following cardiovascular risk factors were available: hyperten-
sion defined as systolic/diastolic blood pressure�140/90 mmHg or use of antihypertensive
treatment; diabetes as fasting glycemia�1.26 g/L or use of antidiabetics drugs; and dyslipide-
mia as LDL cholesterol�1.9 g/L or use of lipid-lowering treatment.
Statistical analyses
Participant characteristics were examined in three groups: CSF AD cases, population controls,
and CSF controls. Proportions were calculated for categorical variables, and means and stan-
dard deviations were computed for continuous variables. Comparison of CSF AD cases with
both control groups was assessed using a χ2 test or Student t test as appropriate. Comparison
of mean CSF biomarker values between CSF AD cases and CSF controls were adjusted for
memory centers using analysis of covariance. Cumulative percentage of CSF AD cases as a
function of age (in 5-year age groups) were plotted according to the APOE ε4 status (0, 1, 2
alleles); median age in the three groups was compared using the nonparametric Brown–Mood
median test. We then used logistic regression to estimate the odds ratio (OR) of AD according
to APOE genotype, comparing the total population of CSF-determined AD cases to population
controls first and then to CSF controls. The role of age in modifying the association between
APOE genotype and AD was examined in analyses stratified by 5-year age group, ranging
from <55 years to>85 years. The ε3/ε3 group was the reference, and analysis was undertaken
in groups using ε4 status. The nonlinearity of associations with AD as a function of age was
tested using an interaction term between age2 and APOE.
Population attributable fraction (PAF) associated with APOE ε4 (one allele, two alleles) for
AD was plotted as a function of 5-year age group. PAF reflects the fraction of AD cases related
to the presence of the APOE ε4 allele, and its calculation is based on prevalence of APOE ε4
among CSF AD cases (PREVε4) and the ORs associated with APOE ε4: PAF = PREVε4 × (1
− 1/OR) [25]. ORs used for these estimations were those from the analysis comparing CSF AD
cases to population controls.
We also examined whether sex and education affected the age-dependent association
between APOE ε4 and AD using a triple interaction term in the logistic regression model. To
ensure robustness of our findings, the analyses were repeated using controls defined by CSF
biomarkers.
We conducted several post hoc analyses in response to peer review comments. First, as CSF
p-tau 181 was missing for one of the centers (Gothenburg), we examined the impact of
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excluding data from this center on our findings. Second, we calculated the sensitivity and spec-
ificity of carrying�1 APOE ε4 to discriminate CSF AD from controls, and the corresponding
area under receiver operating characteristic (ROC) curves (AUCs) were plotted as a function
of age to compare with previous studies [26]. Third, we estimated the heterogeneity of the
association between APOE and AD in the various centers by stratifying the analyses by mem-
ory center and weighting their effect by the sample size, as in a meta-analysis. We calculated
the I2 statistic to evaluate heterogeneity in these estimates [27]. Finally, we examined the
impact of cardiovascular risk factors on the association between APOE genotype and AD.
These analyses were based on a subsample of the population of CSF AD cases for whom these
data were available and all population controls. Using logistic regression, we first report crude
ORs, followed by analyses adjusted for sex and education and, finally, for hypertension, diabe-
tes mellitus, and hypercholesterolemia.
All resulting p-values were two-tailed, and p� 0.05 was considered statistically significant.
Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and
STATA version 14.
Results
A total of 1,593 CSF AD cases, 11,723 population controls, and 805 CSF controls were included
in the analyses; their characteristics are summarized in Table 1. Compared with CSF controls
and population controls, CSF AD cases were older (72.8 versus 67.1 and 65.6 years), more
Table 1. Characteristics of the study population: CSF-determined AD cases, CSF-determined controls, and population controls.
CSF AD cases CSF controls Population controls
Characteristics (N = 1,593) (N = 805) (N = 11,723) p-Valuea p-Valueb
Age, years, mean (SD) 72.8 (8.3) 67.1 (10.3) 65.6 (10.7) <0.001 <0.001
Women, n (%) 883 (55.4) 402 (49.9) 5,525 (47.1) 0.011 <0.001
MMSE, mean (SD)c 21.4 (5.9) 25.6 (4.4) 27.5 (1.8) <0.001 <0.001
Education, n (%)d 0.005 <0.001
Low 83 (6.8) 56 (9.3) 612 (5.2)
Medium 334 (27.3) 195 (32.4) 9,079 (77.4)
High 805 (65.9) 350 (58.2) 2,032 (17.3)
APOE genotype, n (%) <0.001 <0.001
ε2/ε2 3 (0.2) 2 (0.2) 73 (0.6)
ε2/ε3 67 (4.2) 113 (14.0) 1,440 (12.3)
ε3/ε3 514 (32.3) 518 (64.3) 7,560 (64.5)
ε2/ε4 43 (2.7) 8 (1.0) 220 (1.9)
ε3/ε4 701 (44.0) 161 (20.0) 2,267 (19.3)
ε4/ε4 265 (16.6) 3 (0.4) 163 (1.4)
CSF biomarkers, pg/mL, mean (SD)
CSF Aβ42 357.4 (177.5) 803.6 (346.7) — <0.001e
CSF tau 535.3 (400.4) 181.3 (88.7) — <0.001e
CSF p-tau 181 83.2 (49.9) 35.0 (12.8) — <0.001e
aComparison between CSF AD cases and CSF controls, χ2 test or Student t test.
bComparison between CSF AD cases and population controls, χ2 test or Student t test.
cMMSE data were missing for 108 CSF AD, 41 CSF controls, and 4,186 population controls.
dEducation data were missing for 371 CSF AD and 204 CSF controls.
eAnalyses on CSF biomarkers were adjusted for memory center and analysis of covariance.
Abbreviations: Aβ, β-amyloid; AD, Alzheimer disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; MMSE: Mini-Mental State Examination; p-Tau 181, tau
phosphorylated at threonine 181; SD, standard deviation
https://doi.org/10.1371/journal.pmed.1003289.t001
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likely to be women (55.4% versus 49.9% and 47.1%), and had a lower MMSE score (21.4 versus
25.6 and 27.5). CSF cases were also more likely to carry at least one APOE ε4 allele (46.7% ver-
sus 21.0% and 21.2%) or two ε4 alleles (16.6% versus 0.4% and 1.4%). The proportion of APOE
ε4 carriers did not differ between population controls and CSF controls (respectively, 22.6%
and 21.4%, p = 0.41).
Fig 1 presents the cumulative proportion of CSF AD cases as a function of age and APOE
ε4 status. The median age at AD diagnosis of non-ε4 carriers (75.2 years) was greater than that
of one ε4 carriers (73.8 years, p = 0.016) and of ε4/ε4 carriers (70.3 years, p< 0.001). Com-
pared with non-ε4 carriers, the cumulative percentage of AD cases in two ε4 carriers was
higher starting at age 63.5 years, and in one ε4 carriers, the percentage was higher starting at
69.1 years.
The unadjusted association of APOE genotypes with AD is presented in Table 2. The pres-
ence of at least one ε4 allele was associated with an OR of 5.9 (95% confidence interval [CI]
5.3–6.6; p< 0.001) compared with non-ε4 carriers. Using ε3/ε3 as the reference, ε2 allele was
associated with lower risk of AD (OR: 0.68 [0.53–0.88]; p = 0.003), whereas ε2/ε4 (OR: 2.9
[2.0–4.0]; p< 0.001), ε3/ε4 (OR: 4.5 [4.0–5.1]; p< 0.001), and ε4/ε4 (OR: 23.9 [19.3–29.6];
p< 0.001) were associated with greater risk of AD. Using CSF controls instead of population
controls yielded similar findings (Table 2), as well as the exclusion of the center with missing
data for CSF phosphorylated tau (see S2 Table).
The proportion of APOE ε4 carriers by 5-year age group is shown in Fig 2. In total, 28.9%
of CSF AD cases <55 years at diagnosis carried one ε4 allele, and this rate increased
Fig 1. Cumulative proportion of CSF AD cases as a function of age and APOE ε4 status. The dashed horizontal line
shows the median of distribution per group of APOE ε4 status. AD, Alzheimer disease; APOE, apolipoprotein E; CSF,
cerebrospinal fluid.
https://doi.org/10.1371/journal.pmed.1003289.g001
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progressively to 54.2% in the group aged 65–70 years and then progressively decreased to
28.1% in those over 85 years at AD diagnosis. Similarly, 8.9% of AD cases <55 years at diagno-
sis were homozygous ε4/ε4; this proportion climbed progressively to 29.3% in the group aged
60–65 years and then progressively decreased (3.7% in those�85 years). Among population
controls, the proportion of APOE ε4 carriers was around 25% until 65 years old, 20% between
65 and 80 years old, and 15% after the age of 80 years. The distribution of APOE ε4 as a func-
tion of age was similar in population controls and CSF controls (χ2 test, p = 0.42).
The PAF associated with the presence of at least one APOE ε4 allele for AD in the total pop-
ulation was 53%; the PAF by 5-year age categories is presented in Fig 3. PAF associated with at
least one ε4 was highest in the group aged 65–70 years, at 69.7%. The PAF associated with one
ε4 allele was also highest in the group aged 65–70 years, at 48.0%. The PAF of two ε4 alleles
was highest in the group aged 60–65 years, at 28.4%. The importance of ε4 for AD was lower
both at younger (<55 years, PAF: 14.2%) and older (>85 years, PAF: 22.6%) ages.
Fig 4 shows the association of APOE genotype with AD as a function of 5-year age group,
adjusted for sex and education. There was no evidence that the age-related association of
APOE ε4 differed by sex (p = 0.77) or education (p = 0.61). The association of APOE ε4 geno-
type with AD was modified by age (p for interaction with age2 < 0.001), with the strongest
association in the 65–70 age group: one ε4 allele (OR: 10.7 [7.6–15.2]; p< 0.001), ε4/ε4 (OR:
64.2 [34.1–120.8]; p< 0.001). The protective association of APOE ε2 genotype for risk of AD
was not affected by age (p for interaction = 0.72).
Post hoc analysis
Sensitivity and specificity of APOE ε4 to discriminate CSF AD from population controls was,
respectively, 56% and 78% for heterozygotes and 31% and 98% for homozygotes, correspond-
ing to an AUC of 0.70 (0.69–0.72, p< 0.001); similar results were found when comparing CSF
AD cases with CSF controls (AUC = 0.70 [0.69–0.73], p< 0.001). The ability of APOE ε4 to
discriminate AD from controls differed as a function of age (Fig 5) and was greatest in the
Table 2. The ORs of AD according to APOE genotype. CSF AD cases were compared with population controls and
with CSF controls using logistic regression analysis.
CSF AD cases versus
population controls
CSF AD cases versus
CSF controls
APOE genotype OR (95% CI) p-Value OR (95% CI)a p-Valuea
0 ε4 1 (Ref) 1 (Ref)
�1 ε4 5.9 (5.3–6.6) <0.001 6.4 (5.2–7.7) <0.001
0 ε4 1 (Ref) 1 (Ref)
1 ε4 4.6 (4.1–5.2) <0.001 4.8 (3.9–5.8) <0.001
2 ε4 25.4 (20.4–31.2) <0.001 — —
ε2/ε2, ε2/ε3 0.68 (0.53–0.88) 0.003 0.61 (0.44–0.85) 0.003
ε3/ε3 1 (Ref) 1 (Ref)
ε2/ε4 2.9 (2.0–4.0) <0.001 — —
ε3/ε4 4.5 (4.0–5.1) <0.001 4.4 (3.6–5.4) <0.001
ε4/ε4 23.9 (19.3–29.6) <0.001 — —
OR could not be determined due to small numbers in the following CSF control categories: ε4/ε4 (n = 3) and ε2/ε4
(n = 8) categories.
Abbreviations: AD, Alzheimer disease; APOE, apolipoprotein E; CI, confidence interval; CSF, cerebrospinal fluid;
OR, odds ratio; Ref, reference
https://doi.org/10.1371/journal.pmed.1003289.t002
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Fig 2. APOE ε4 prevalence in CSF AD cases and population and CSF controls as a function of age group. AD,
Alzheimer disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid.
https://doi.org/10.1371/journal.pmed.1003289.g002
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group aged 65–69 years (AUC = 0.78 [0.75–0.80], p< 0.001) and poorer before 55 years
(AUC = 0.55 [0.47–0.62], p = 0.32) and after 85 years (AUC = 0.61 [0.56–0.67], p = 0.001).
We examined the heterogeneity in associations of one or more APOE ε4 with AD across
the different memory centers using population controls as the comparison group. These
results are shown in Fig 6. The I2 statistic was 58%, corresponding to some heterogeneity
between centers.
The final analysis was on the subset of patients with AD (841 CSF AD cases) with data on
cardiovascular risk factors. There were no significant differences between CSF AD cases with
and without these data in term of age (p = 0.80) and APOE genotype (p = 0.67). Compared
with general population controls (see S3 Table), CSF AD cases were more likely to have hyper-
tension (p = 0.024), diabetes mellitus (p< 0.001), and hypercholesterolemia (p< 0.001). We
examined the role of these risk factors in the association of APOE genotypes with AD without
adjustment for age due to its role in modifying the association between APOE genotype and
AD. Table 3 shows these results. Adjustment for sex and education (model 1) and for cardio-
vascular risk factors (model 2) had little impact on the estimates compared with the unadjusted
model. S1 Fig shows similar findings in analyses stratified by age group.
Discussion
In this large multicentric study that included 1,600 biomarker-positive AD cases, we showed
that the association between APOE ε4 and AD is modified by age. The impact of ε4 was less
pronounced before the age of 60, strongest between 65 and 70 years, and then declined pro-
gressively at older ages. APOE ε4 carriers were more likely to develop AD at younger ages,
Fig 3. Population attributable fraction of APOE ε4 for AD by 5-year age group. AD, Alzheimer disease; APOE,
apolipoprotein E.
https://doi.org/10.1371/journal.pmed.1003289.g003
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with a difference of 4.9 years for ε4/ε4 and 1.4 years for one ε4 carriers when compared with
median age at AD diagnosis in non-ε4 carriers (75.2 years). The PAF associated with APOE ε4
for AD was 53% overall, but it varied strongly with age, following a bell-curve relationship that
ranged from less than 20% in the youngest and the oldest age groups and reaching 70%
between 65 and 70 years. The protective effect of APOE ε2 allele was unaffected by age. The
association between APOE genotype and AD was first reported in 1993 [28], and age is thought
to play a role in this association [29,30]. Our use of a large, multicentric study of patients with
AD defined by the new A/T/N criteria allows the risk of misclassification bias to be addressed,
as it can be critical in such analyses. A further advantage of our study is the use of population
controls from two large longitudinal cohorts in which the follow-up allowed us to remove inci-
dent cases of dementia. Because this control group without clinical dementia may be positive
on AD biomarkers, we also considered a second group of controls drawn from the same mem-
ory clinics as the AD cases. This group of controls had a normal CSF AD biomarker profile,
Fig 4. Association of APOE genotype in CSF-determined AD cases compared with population controls. Genotype ε3/ε3 was used as reference. p-Value is for
interaction between age2 and APOE. Error bars correspond to the standard errors of the ORs calculated by 5-year age categories. Association between age and OR of AD
(curves in the graphs) was modeled using a quadratic term for age in the logistic regression model and adjusted for sex and education. AD, Alzheimer disease; APOE,
apolipoprotein E; CSF, cerebrospinal fluid; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003289.g004
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and results using these two independent sets of controls were similar, suggesting that our find-
ings are robust.
In our study, carrying at least one APOE ε4 allele was associated with a 5.9 (5.3–6.6;
p< 0.001) higher OR of AD, compared with an OR of 3.3 (3.2–3.4; p< 0.001) reported by a
recent meta-analysis of 46 case–control studies with 64,000 participants [31]. We found the
overall PAF associated with one or more APOE ε4 allele to be 53%, compared with the 37%
reported by the AlzGene meta-analysis [32]. Our estimates are higher than those previously
reported from studies based on only clinical AD criteria [33] but are close to those reported
when using neuropathology [34] or biomarker approaches for AD diagnoses [35,36]. Our
results, along with recent findings from other studies, suggest that the impact of APOE ε4, par-
ticularly ε4 homozygotes, is underestimated in studies based exclusively on clinical criteria for
AD diagnosis [37]. A possible explanation is the importance of APOE ε4 specifically for AD
neuropathology [38]. Another explanation is linked to the key finding that the association
between APOE ε4 and AD is mediated by age. Therefore, a single, overall OR may not be suit-
able; reporting age-specific ORs, as in our analyses, may facilitate comparison between studies.
Our findings have implications for several types of studies, e.g., epidemiological and
genetic, aiming to reveal biological associations between environmental and genetic risk fac-
tors for AD, which generally are performed on clinically diagnosed patients and cognitively
unimpaired controls, without biomarker data. Midlife vascular risk factors (obesity, smoking,
diabetes, hypertension, and cardiac disease) have commonly been found to increase risk of
cognitive decline and AD dementia defined using clinical criteria; population studies employ-
ing biomarkers show that such risk factors are associated with neurodegeneration but not
brain amyloidosis [39]. Further, genome-wide association studies have identified loci
Fig 5. Analysis of the AUC in function of age for at least one APOE ε4 carrying versus none to discriminate CSF
AD from population controls. AD, Alzheimer disease; APOE, apolipoprotein E; AUC, area under receiver operating
characteristic curve; CI, confidence interval; CSF, cerebrospinal fluid.
https://doi.org/10.1371/journal.pmed.1003289.g005
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associated with clinically defined AD, but when examined in autopsy cohorts, no associations
were found with plaques or tangle pathology; instead, associations were found with
Fig 6. Association between APOE ε4 carrying and AD stratified by center, using general population group as
controls. AD, Alzheimer disease; APOE, apolipoprotein E; CI, confidence interval; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003289.g006
Table 3. The ORs of AD in CSF AD cases compared with population controls: multivariable logistic regression analysis.
Unadjusted Model 1a Model 2b
APOE OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value
0 ε4 1 (Ref) 1 (Ref) 1 (Ref)
�1 ε4 5.9 (5.1–6.8) <0.001 6.0 (5.1–7.0) <0.001 6.0 (5.1–7.0) <0.001
0 ε4 1 (Ref) 1 (Ref) 1 (Ref)
1 ε4 4.7 (4.0–5.4) <0.001 4.7 (4.0–5.6) <0.001 4.7 (4.0–5.6) <0.001
2 ε4 24.6 (19.0–31.7) <0.001 25.7 (19.0–34.7) <0.001 26.5 (19.5–36.1) <0.001
ε2/ε2, ε2/ε3 0.55 (0.38–0.81) 0.002 0.54 (0.37–0.79) 0.002 0.53 (0.36–0.78) 0.001
ε3/ε3 1 (Ref) 1 (Ref) 1 (Ref)
ε2/ε4 2.5 (1.5–3.9) <0.001 2.3 (1.4–3.9) <0.001 2.3 (1.4–3.8) 0.001
ε3/ε4 4.5 (3.8–5.3) <0.001 4.6 (3.8–5.4) <0.001 4.6 (3.8–5.5) <0.001
ε4/ε4 22.7 (17.6–29.4) <0.001 23.7 (17.4–32.1) <0.001 24.5 (18.0–33.4) <0.001
Analyses were performed on a subsample (N = 841 AD cases, 11,665 controls).
aModel 1: adjustment for sex and education.
bModel 2: model 1 + further adjustment for hypertension, diabetes, and hypercholesterolemia.
Abbreviations: AD, Alzheimer disease; APOE, apolipoprotein E; CI, confidence interval; CSF, cerebrospinal fluid; OR, odds ratio; Ref, reference
https://doi.org/10.1371/journal.pmed.1003289.t003
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cerebrovascular disease [40]. Thus, there is a need to reinvestigate possible associations
between environmental and genetic risk factors for AD using biomarker-based studies to
understand the biologic basis of such associations.
Causes of early-onset AD, before 65 years, remain poorly understood. Autosomal dominant
mutations, affecting amyloid precursor protein (APP), presenilin-1 (PSEN1), or presenilin-2
(PSEN2) genes, are thought to be involved, but these mutations are rare, accounting for less
than 10% of early-onset AD [1]. During this past decade, several genome-wide association
studies have discovered around 30 risk loci of the disease, which are useful to identify novel
insights into the neurobiology of the disease, but their contribution to explaining AD in the
population is thought not to be substantial [10]. Conversely, recent efforts in whole-exome
and whole-genome sequencing of large AD case–control series unraveled three major genes—
sortilin-related receptor (SORL1); triggering receptor expressed on myeloid cells-2 (TREM2);
and ATP-binding cassette, sub-family A, member 7 (ABCA7)—the rare coding variants of
which significantly increase the risk of AD with moderate to high OR [41]. Interestingly, the
ORs were higher in patients with early-onset AD [41], and some patients carried more than
one strong risk factor, including APOE ε4, suggesting an oligogenic inheritance in some of
these patients.
In our study, APOE ε4 did not play a strong role in risk of AD before the age of 60 years,
whereas its role increased dramatically during the seventh decade to hit its peak by 70 years.
Asymptomatic APOE ε4 carriers are a major target for potential disease-modifying drugs to
prevent AD, and several clinical trials are currently ongoing on this population [42]. Our find-
ings support the idea of an early intervention in this population, if and when available, before
APOE ε4 carriers reach the age at which incidence of AD rises sharply.
Strengths and limitations
This study has several strengths, including the use of AD cases determined using CSF bio-
markers for tau and Aβ; a large sample size, which allowed sufficient power to undertake anal-
ysis in 5-year age categories; as well as the use of two large population cohort studies with long
follow-up data, allowing us to exclude incident cases of dementia. Furthermore, we were able
to replicate findings using a further set of controls, consisting of persons with normal CSF bio-
markers who were seen at the same memory centers as the AD cases. The distribution of
APOE genotypes by age group was similar in the two sets of controls, and the associations with
AD using the two types of controls were also similar.
This study needs to be considered in light of the following limitations. First, AD cases
drawn from memory centers may not be representative of the general population of patients
with AD, in particular patients who do not seek medical care. This may involve some selection
bias, primarily due to sociodemographic factors like education or sex, but it is unlikely to be a
source of major bias because APOE status is unlikely to affect the decision to consult at mem-
ory clinics. Second, data on cardiovascular risk factors or familial history were missing for a
part of the CSF AD cases, and adjustment for these risk factors was possible only on a subsam-
ple. More-detailed data on a larger set of risk factors would be useful in future studies to better
understand the mechanisms underlying the relationship between APOE and AD. Third, the
overall ratio between AD cases and controls used in this study was around 1:7, which may lead
to detection of nonpertinent associations due to an overpowered design. However, the value of
a large sample size is the ability to examine the association between APOE and AD in age sub-
groups to show the manner in which age modifies this association [43]. Finally, these analyses
were restricted to white populations because the APOE ε4 allele frequency as well as its associa-
tion with AD risk may be strongly influenced by ethnicity and geographic region [44,45].
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Further research using different population settings is needed to better understand these com-
plex associations.
Conclusions
This study supports an association between APOE ε4 and the risk of AD evaluated using bio-
markers of AD neuropathology, and the results suggest that the strength of this association
varies by age. The effect of APOE ε4 on AD was less pronounced in both younger and older
persons (less than 60 and more than 85 years) and was greatest between 65 and 70 years, with a
population attributable risk of 70% in this group. These findings highlight the importance of
early interventions, if and when available, to mitigate the effect of APOE ε4 on AD.
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de la Santé et de la Recherche Médicale (INSERM), the Victor Segalen-Bordeaux II University,
and the Sanofi-Synthélabo Company.
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